To determine the effects of norepinephrine and levosimendan on microvascular perfusion and oxygenation in a rat model of septic shock.
Controlled laboratory animal study.
Research laboratory in a university hospital.
Forty Sprague-Dawley rats.
Sepsis was induced in 32 animals by cecal ligation and puncture. Eight animals served as sham controls. Animals were randomly assigned to five groups: 1) fluid resuscitation (25 ml·kg−1·h−1), 2) fluid resuscitation plus norepinephrine (0.5 μg·kg−1·min−1), 3) fluid resuscitation plus levosimendan (0.3 μg·kg−1·min−1), 4) no treatment and 5) sham control.
Microvascular perfusion was quantitated using sidestream darkfield imaging and microvascular oxygenation (μPO2) was assessed by oxygen-dependent quenching of phosphorescence. Measurements were obtained on the buccal mucosa at baseline and at hourly intervals thereafter. In parallel, cardiac output (CO) was recorded. After induction of sepsis microvascular perfusion and μPO2 were impaired early followed by significant decreases in CO. Although levosimendan and norepinephrine were equally effective in restoring CO, only treatment with levosimendan significantly improved μPO2 after 1 and 2 hours of treatment (9.7 ± 2.0 vs. 15.1 ± 2.6 and 16.0 ± 3.7 mmHg; p < 0.05). Microvascular perfusion was not significantly influenced by any of the treatment strategies.
In this model, treatment with levosimendan and norepinephrine showed comparable effects in restoring CO and had no significant influence on microvascular perfusion. However, only levosimendan significantly improved μPO2, suggesting that a mechanism relatively independent of macrocirculatory hemodynamics and overall microvascular perfusion might account for these observations.
From the Department of Anesthesiology (MF, RR, CB, JB, SR), University Hospital RWTH Aachen, Aachen, Germany; Department of Intensive Care Medicine (CI), and Department of Anesthesiology (EGM), Erasmus Medical Centre, University of Rotterdam, Rotterdam, The Netherlands.
*See also p. 1981.
Dr. Fries has received grants from Deutsche Interdisziplinare Vereinigung Intensivmedizin and Abbott GmbH & Co. KG. Dr. Ince is chief scientific officer of Microvision Medical, which commercializes the SDF imaging used in this study; and he holds patents, a consultancy, and shares in that company.
The remaining authors have not disclosed any potential conflicts of interest.
For information regarding this article, E-mail: firstname.lastname@example.org